Admoral is a R&D Center that focuses on the "process development" of generic generic drugs and anti-tumor generic drugs and their intermediates.To meet the needs of customers, based on the premise of the best quality and reasonable price, establish core technology, develop the most competitive and non-infringing high-quality manufacturing process, taking into quality, safety, environmental protection, GMP standards and corporate social responsibility。
From R&D item selection, process development, production line design, GMP regulations and product sales... etc., comprehensive planning, development, technology transfer and marketing, in order to shorten the development timeline and sales risk of API manufacturers, and cooperate with API manufacturers to create mutually beneficial business opportunities.
Item Number | Product Name | Indications |
---|---|---|
01 | Apixaban | Anticoagulant |
02 | Bicalutamide | Metastatic prostate cancer |
03 | Dasatinib | Chronic myeloid leukemia |
04 | Erlotinib HCI | Non-small cell lung cancer |
05 | Gefitinib | Non-small cell lung cancer |
06 | Indacaterol maleate | Chronic obstructive pulmonary disease |
07 | Linagliptin | Type 2 diabetes |
08 | Nilotinib HCI | Blood cancer |
09 | Paliperidone Palmitate | Mental/Mood disorders |
10 | Rivaroxaban | Anticoagulant |
11 | Sorafenib Tosylate | Renal cell carcinoma |
12 | Sunitinib Malate | Gastrointestinal stromal tumors |
13 | Mephenoxalone | Muscle relaxant |